| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:50 UTC |
|---|
| Update Date | 2022-03-07 02:51:45 UTC |
|---|
| HMDB ID | HMDB0014834 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Ergotamine |
|---|
| Description | Ergotamine is only found in individuals that have used or taken this drug. It is a vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders. [PubChem]Ergotamine acts on migraine by one of two proposed mechanisms: 1) activation of 5-HT1D receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache, and 2) activation of 5-HT1D receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release. |
|---|
| Structure | [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (5'alpha)-12'-Hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione | ChEBI | | 12'-Hydroxy-2'-methyl-5'alpha-(phenylmethyl)ergotaman-3',6',18-trione | ChEBI | | Ergotamin | ChEBI | | Ergotamina | ChEBI | | Ergotaminum | ChEBI | | Gynergen | ChEBI | | (5'a)-12'-Hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione | Generator | | (5'Α)-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione | Generator | | 12'-Hydroxy-2'-methyl-5'a-(phenylmethyl)ergotaman-3',6',18-trione | Generator | | 12'-Hydroxy-2'-methyl-5'α-(phenylmethyl)ergotaman-3',6',18-trione | Generator | | Cornutamine | HMDB | | Ergotaminine | HMDB | | Lingraine | HMDB | | Tartrate, ergotamine | HMDB | | ErgoKranit | HMDB | | Ergo-kranit | HMDB | | Ergotamine tartrate (2:1) | HMDB | | mono, Ergodryl | HMDB | | Pfizer brand OF ergotamine tartrate | HMDB | | Ergo sanol | HMDB | | Ergo kranit | HMDB | | Ergodryl mono | HMDB | | Ergomar | HMDB | | Ergostat | HMDB | | Ergotamine tartrate | HMDB | | Krewel brand OF ergotamine tartrate | HMDB | | Lotus brand OF ergotamine tartrate | HMDB | | Sanofi winthrop brand OF ergotamine tartrate | HMDB |
|
|---|
| Chemical Formula | C33H35N5O5 |
|---|
| Average Molecular Weight | 581.6615 |
|---|
| Monoisotopic Molecular Weight | 581.263819255 |
|---|
| IUPAC Name | (4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.0²,⁶]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide |
|---|
| Traditional Name | ergomar |
|---|
| CAS Registry Number | 113-15-5 |
|---|
| SMILES | [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)C4=C3)O[C@@]21O |
|---|
| InChI Identifier | InChI=1S/C33H35N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,15,17,21,25-27,34,42H,7,12-14,16,18H2,1-2H3,(H,35,39)/t21-,25-,26+,27+,32-,33+/m1/s1 |
|---|
| InChI Key | XCGSFFUVFURLIX-VFGNJEKYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as ergotamines, dihydroergotamines, and derivatives. These are organic compounds containing an ergotamine moiety, which is structurally characterized by a benzyl substituent attached to the piperazine ring of the ergopeptine backbone. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Alkaloids and derivatives |
|---|
| Class | Ergoline and derivatives |
|---|
| Sub Class | Lysergic acids and derivatives |
|---|
| Direct Parent | Ergotamines, dihydroergotamines, and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Ergotamine
- Hybrid peptide
- Alpha-dipeptide
- Lysergic acid amide
- Indoloquinoline
- Benzoquinoline
- Quinoline-3-carboxamide
- N-acyl-alpha amino acid or derivatives
- Pyrroloquinoline
- Quinoline
- Alpha-amino acid or derivatives
- 3-alkylindole
- Indole
- Indole or derivatives
- Isoindole or derivatives
- Aralkylamine
- N-alkylpiperazine
- Monocyclic benzene moiety
- 1,4-diazinane
- Benzenoid
- Oxazolidinone
- Piperazine
- Pyrrole
- Pyrrolidine
- Heteroaromatic compound
- Oxazolidine
- Tertiary carboxylic acid amide
- Carboxamide group
- Tertiary amine
- Amino acid or derivatives
- Lactam
- Tertiary aliphatic amine
- Secondary carboxylic acid amide
- Orthocarboxylic acid derivative
- Carboxylic acid derivative
- Organoheterocyclic compound
- Alkanolamine
- Oxacycle
- Azacycle
- Organooxygen compound
- Organic nitrogen compound
- Organopnictogen compound
- Carbonyl group
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Amine
- Organonitrogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 213.5 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.22 g/L | Not Available | | LogP | 2 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.33 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 12.3614 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 4.11 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 82.9 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2167.2 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 175.1 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 203.5 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 177.5 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 170.6 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 390.0 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 433.0 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 569.5 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1088.3 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 507.0 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1627.6 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 339.3 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 362.3 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 295.4 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 328.1 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 9.9 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Ergotamine,1TMS,isomer #1 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C=C2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 4759.5 | Semi standard non polar | 33892256 | | Ergotamine,1TMS,isomer #2 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C=C2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 4622.8 | Semi standard non polar | 33892256 | | Ergotamine,1TMS,isomer #3 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C=C2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 4694.6 | Semi standard non polar | 33892256 | | Ergotamine,2TMS,isomer #1 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C=C2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 4639.4 | Semi standard non polar | 33892256 | | Ergotamine,2TMS,isomer #1 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C=C2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 4731.6 | Standard non polar | 33892256 | | Ergotamine,2TMS,isomer #1 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C=C2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 6233.0 | Standard polar | 33892256 | | Ergotamine,2TMS,isomer #2 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C=C2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 4672.6 | Semi standard non polar | 33892256 | | Ergotamine,2TMS,isomer #2 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C=C2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 4660.1 | Standard non polar | 33892256 | | Ergotamine,2TMS,isomer #2 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C=C2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 6234.2 | Standard polar | 33892256 | | Ergotamine,2TMS,isomer #3 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C=C2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 4573.6 | Semi standard non polar | 33892256 | | Ergotamine,2TMS,isomer #3 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C=C2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 4689.0 | Standard non polar | 33892256 | | Ergotamine,2TMS,isomer #3 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C=C2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 6231.5 | Standard polar | 33892256 | | Ergotamine,3TMS,isomer #1 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C=C2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 4600.6 | Semi standard non polar | 33892256 | | Ergotamine,3TMS,isomer #1 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C=C2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 4680.6 | Standard non polar | 33892256 | | Ergotamine,3TMS,isomer #1 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O[Si](C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C)C=C2C3=CC=CC4=C3C(=CN4[Si](C)(C)C)C[C@H]21 | 5987.9 | Standard polar | 33892256 | | Ergotamine,1TBDMS,isomer #1 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O[Si](C)(C)C(C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C=C2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 4942.8 | Semi standard non polar | 33892256 | | Ergotamine,1TBDMS,isomer #2 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C(C)(C)C)C=C2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 4830.5 | Semi standard non polar | 33892256 | | Ergotamine,1TBDMS,isomer #3 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C=C2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 4878.3 | Semi standard non polar | 33892256 | | Ergotamine,2TBDMS,isomer #1 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O[Si](C)(C)C(C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C(C)(C)C)C=C2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 5016.2 | Semi standard non polar | 33892256 | | Ergotamine,2TBDMS,isomer #1 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O[Si](C)(C)C(C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C(C)(C)C)C=C2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 5151.3 | Standard non polar | 33892256 | | Ergotamine,2TBDMS,isomer #1 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O[Si](C)(C)C(C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C(C)(C)C)C=C2C3=CC=CC4=C3C(=C[NH]4)C[C@H]21 | 6256.1 | Standard polar | 33892256 | | Ergotamine,2TBDMS,isomer #2 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O[Si](C)(C)C(C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C=C2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 5038.1 | Semi standard non polar | 33892256 | | Ergotamine,2TBDMS,isomer #2 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O[Si](C)(C)C(C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C=C2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 5060.0 | Standard non polar | 33892256 | | Ergotamine,2TBDMS,isomer #2 | CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O[Si](C)(C)C(C)(C)C)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)C=C2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 6288.3 | Standard polar | 33892256 | | Ergotamine,2TBDMS,isomer #3 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C(C)(C)C)C=C2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 4952.8 | Semi standard non polar | 33892256 | | Ergotamine,2TBDMS,isomer #3 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C(C)(C)C)C=C2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 5076.9 | Standard non polar | 33892256 | | Ergotamine,2TBDMS,isomer #3 | CN1C[C@H](C(=O)N([C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](CC4=CC=CC=C4)N3C2=O)[Si](C)(C)C(C)(C)C)C=C2C3=CC=CC4=C3C(=CN4[Si](C)(C)C(C)(C)C)C[C@H]21 | 6283.9 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Ergotamine GC-MS (Non-derivatized) - 70eV, Positive | splash10-0gi0-6692120000-7fabddfa08a8dd219bc3 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Ergotamine GC-MS (1 TMS) - 70eV, Positive | splash10-0g4j-9281023000-06e454bbac7ea8189ead | 2017-10-06 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Ergotamine GC-MS ("Ergotamine,1TMS,#1" TMS) - 70eV, Positive | Not Available | 2021-10-14 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Ergotamine GC-MS (TMS_1_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Ergotamine GC-MS (TMS_1_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Ergotamine GC-MS (TBDMS_1_1) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Ergotamine GC-MS (TBDMS_1_2) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Ergotamine GC-MS (TBDMS_1_3) - 70eV, Positive | Not Available | 2021-10-15 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ergotamine 10V, Positive-QTOF | splash10-001i-0022090000-66faf61c3242915f91f8 | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ergotamine 20V, Positive-QTOF | splash10-0uyi-0091010000-98b25c5586801771014a | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ergotamine 40V, Positive-QTOF | splash10-00di-4290000000-42f48d5180d5f2f5c20e | 2016-08-01 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ergotamine 10V, Negative-QTOF | splash10-0019-0049160000-6be92986c4d5c2bd6dad | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ergotamine 20V, Negative-QTOF | splash10-0aor-2196220000-c51c3bf00ec927a5631b | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ergotamine 40V, Negative-QTOF | splash10-0g5a-9810000000-7522033f4e775f417ffa | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ergotamine 10V, Positive-QTOF | splash10-001i-0000090000-34b8023f9528c85e96bc | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ergotamine 20V, Positive-QTOF | splash10-001i-0020190000-ec8f5848bc681f03dbe9 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ergotamine 40V, Positive-QTOF | splash10-00di-0090020000-c4d316e57df458ef5f72 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ergotamine 10V, Negative-QTOF | splash10-001i-0000090000-7dfa0cf0a740c633816a | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ergotamine 20V, Negative-QTOF | splash10-001i-2100390000-8129f2d9526dbde472d8 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Ergotamine 40V, Negative-QTOF | splash10-0fvi-9252430000-c9d112acb2b7bf8de124 | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|